Abstract

FORMULATION AND EVALUATION OF TRANSDERMAL PATCHES OF GLIBENCLAMIDE

Dr. Khaja Pasha* and Dr. Shahana Banu

ABSTRACT

The objective of present study was to develop matrix type transdermal therapeutic systems of Glibenclamide using various hydrophilic (HPMC) and hydrophobic (EUDRAGID) polymers as matrix formers. Results revealed that prepared patches showed good physical characteristics, no drug-polymer interaction and no skin irritation was observed. The in vitro release study revealed that F3 formulation showed maximum release in 24hrs. Formulation F3 was subjected for accelerated stability studies. The F3 formulation was found to be stable as there was no drastic change in the Physico-chemical properties of the patches, which was also confirmed by FTIR. Thus conclusion can be made that stable transdermal patches of Glibenclamide has been developed. F1, F2, F3, F4 formulations showed highest cumulative percentage drug release of 98.13%, 95.50%, 98.65%, 97.21% were obtained during in vitro drug release studies after 24 hrs. The release of Glibenclamide appears to be dependent on lipophilicity of the matrix. Moderately lipophillic matrices showed best release. The predominant release mechanism of drug through the fabricated matrices was believed to be by diffusion mechanism. Based upon the in vitro dissolution data the F3 formulation was concluded as optimized formulation.

Keywords: Glibenclamide, Ethyl cellulose, Sodium alginate, Poly ethylene glycol.